comprehensive -WSS

comprehensive

author：explore 2025-09-29 21:26:11 - browse：57

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Readout Newsletter: Bristol, Sangamo, Gilead, and more

knowledge

WSS

The inclusion problem at the heart of rehabilitation research

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Cardiologists urge adding sexual orientation, gender identity to health records

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

HPV vaccine, cervical cancer study delivers historic results

As AI in medicine takes off, can 'human in the loop' prevent harm?

knowledge

comprehensive

hotspot

In Memoriam: Notable people who died in 2023

HPV vaccine, cervical cancer study delivers historic results

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Peter Hotez and the public health issue of online harassment

FDA advisers back CAR

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Mass General, Mayo Clinic look to monetize custom

Drug repurposing or repositioning? The language matters

As AI in medicine takes off, can 'human in the loop' prevent harm?

explore

John Green on his newest strategy for fighting tuberculosis

Readout Newsletter: Bristol, Sangamo, Gilead, and more

There's an unseen cost to disruptive road

As AI in medicine takes off, can 'human in the loop' prevent harm?

Pumping milk in bathrooms at health conferences is common

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

hotspot

knowledge

knowledge

explore